Q1 2021 Corcept Therapeutics Inc Earnings Call Transcript
Good day, and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. (Operator Instructions)
At this time, I'd like to turn the conference over to Atabak Mokari. Please go ahead.
Good afternoon. I'm Atabak Mokari, Corcept's Chief Financial Officer. Today, we issued 3 press releases: one, announcing the positive outcome of our 178-patient Phase II trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer.
Second, announcing markedly decreased liver fat in patients in our Phase II trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis of NASH; and the third, providing a clinical update and announcing our financial results for the first quarter. Copies of all of these are available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.
Today's call is being recorded. A replay will be available on the Investors Past
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |